IAVI Statement in Response to MDP 301 Phase III Trial of a Vaginal Microbicide
The International AIDS Vaccine Initiative released a statement congratulating the partners involved in the MDP 301 Phase III clinical trial of a vaginal microbicide on the successful conduct of the largest microbicide trial completed to date. IAVI said the trial itself provided other achievements that will help advance microbicide development and HIV prevention research generally. Please see the below attachment for the full statement.
|IAVI Statement_micorbicide.pdf||12.3 KB|